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Abstract
Background Icosapent ethyl (IPE) is a high-purity
prescription form of eicosapentaenoic acid ethyl ester
approved by the US Food and Drug Administration as an
adjunct to diet to reduce triglyceride (TG) levels in adult
patients with severe (C500 mg/dL) hypertriglyceridemia.
In addition to TG-lowering effects, IPE also reduces non-
high-density lipoprotein cholesterol and apolipoprotein B
levels without significantly increasing low-density lipo-
protein cholesterol (LDL-C) in patients with very high TG
levels C500 mg/dL (MARINE study) and in patients with
well-controlled LDL-C and residually high TG levels
200–500 mg/dL (ANCHOR study). This analysis exam-
ined the effect of IPE on inflammatory markers in patients
from MARINE and ANCHOR.
Methods MARINE (N = 229) and ANCHOR (N = 702)
were Phase III, double-blind studies that randomized
hypertriglyceridemic patients to IPE 4 g/day, 2 g/day, or
placebo. This analysis assessed the median placebo-
adjusted percentage change from baseline in markers rep-
resenting various stages of atherosclerotic inflammation
such as intercellular adhesion molecule-1 (ICAM-1),
oxidized low-density lipoprotein (Ox-LDL), lipoprotein-
associated phospholipase A2 (Lp-PLA2), interleukin-6
(IL-6), and high-sensitivity C-reactive protein (hsCRP).
Results Compared to placebo, IPE 4 g/day significantly
decreased Ox-LDL (13 %, p \ 0.0001, ANCHOR),
Lp-PLA2 (14 %, p \ 0.001, MARINE; 19 %, p \ 0.0001,
ANCHOR), and hsCRP levels (36 %, p \ 0.01, MARINE;
22 %, p \ 0.001, ANCHOR), but did not significantly
change ICAM-1 and IL-6 levels. In the MARINE study,
IPE 2 g/day did not significantly change ICAM-1,
Ox-LDL, Lp-PLA2, IL-6, or hsCRP levels. Also, compared
to placebo in the ANCHOR study, IPE 2 g/day signifi-
cantly decreased Lp-PLA2 levels (8 %, p \ 0.0001), but
did not significantly change levels of other assessed
inflammatory markers.
Conclusion Compared to placebo, in hypertriglyceri-
demic patients, IPE 4 g/day significantly decreased
Ox-LDL, Lp-PLA2, and hsCRP levels.
1 Introduction
Inflammation plays an important role in all stages of ath-
erosclerosis [1]. Markers of inflammation are often used to
assess cardiovascular risk, and sometimes guide decisions
regarding the treatment of atherosclerotic coronary heart
disease (CHD) [1, 2]. Upon vascular injury, vascular
endothelial cells express vascular adhesion molecules
(such as intercellular adhesion molecule-1 [ICAM-1]), that
facilitate attachment of circulating leukocytes and promote
vascular inflammation, which may help explain the
observed association of vascular adhesion molecules with
increased CHD risk [3, 4]. Concurrently, lipoprotein par-
ticles such as low-density lipoproteins (LDL) may collect
within the intima, where they can undergo oxidation and
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create unstable oxygen free radicals and other reactive
oxygen species [5]. Increased plasma concentrations of
oxidized LDL (Ox-LDL) are thought to help predict future
CHD events [6].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is
an enzyme brought into the arterial intima bound to LDL
particles; it may also be produced by plaque inflammatory
cells [7, 8]. Lp-PLA2 facilitates enzymatic modification of
Ox-LDL particles, hydrolyzing Ox-LDL phospholipids to
lysophosphatidylcholine and oxidized free fatty acids,
which subsequently activate inflammatory macrophages
[8]. Ox-LDL activation of macrophages can also increase
interleukin-6 (IL-6), which may increase adhesion mole-
cule expression, thus promoting vascular inflammation and
potentially worsening atherosclerotic progression [9]. In
clinical practice, the potential contribution of inflammation
to atherosclerosis is most often assessed by C-reactive
protein (CRP), an acute-phase reactant. CRP is produced
by the liver and various other non-hepatic tissues such as
vascular smooth muscle cells [10]. Increased CRP can be
found with inflammatory diseases, as well as in overweight
individuals as a response to increased IL-6 from dysfunc-
tional adipose tissue [11]. Low-grade increases in CRP
levels may also occur in response to increased inflamma-
tory signaling from vascular macrophages associated with
atherosclerosis [10]. Clinical trials have found levels of
Lp-PLA2 and CRP to be higher in patients who developed
CHD and ischemic stroke compared to those who did not
experience these cardiovascular events [12, 13].
Eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are omega-3 fatty acids found in fish oil and in
supplements and prescription formulations [14]. Thera-
peutically, EPA and DHA lower triglyceride (TG) levels
and may reduce cardiovascular events [15]. Icosapent ethyl
(IPE; VascepaTM [formerly AMR101]; Amarin, Bedmin-
ster, NJ, USA) is a high-purity prescription form of EPA
ethyl ester approved by the US Food and Drug Adminis-
tration (FDA) as an adjunct to diet to reduce TG levels in
adult patients with severe (C500 mg/dL) hypertriglyceri-
demia. MARINE (Multi-Center, PlAcebo-Controlled,
Randomized, Double-BlINd, 12-week study with an open-
label Extension) evaluated the efficacy and safety of IPE in
lowering TG levels in 229 patients with very high TG
levels (C500 mg/dL and B2000 mg/dL). In MARINE,
patients were allowed to continue with their statin therapy
if they were deemed to have a high risk for CHD or CHD
risk equivalents and were on a stable dose. ANCHOR
evaluated the efficacy and safety of IPE in lowering TG
levels in 702 statin-treated patients at high cardiovascular
risk with well-controlled LDL-C and residually high TG
levels (C200 mg/dL and \500 mg/dL). In both studies,
IPE 4 g/day significantly lowered TG, non-high-density
lipoprotein cholesterol (non-HDL-C), apolipoprotein B
(apo B), very-low-density lipoprotein cholesterol (VLDL-C),
and total cholesterol (TC) levels, all without significantly
raising LDL-C levels [16, 17]. This current analysis describes
the effects of IPE on the a priori secondary and exploratory
endpoints of the circulating inflammatory markers ICAM-1,
Ox-LDL, Lp-PLA2, IL-6, and high-sensitivity CRP (hsCRP)
observed in MARINE and ANCHOR.
2 Methods
2.1 Design and Patients
MARINE (NCT01047683) and ANCHOR (NCT01047501)
study designs were previously published [16, 17]. Briefly,
both were phase III, placebo-controlled, randomized,
double-blind, multicenter studies with a 4- to 6-week lead-
in period of diet, lifestyle, and medication stabilization
with washout of prohibited lipid-altering medications. In both
studies, eligible men and women aged[18 years with qual-
ifying lipid levels (MARINE: TG C500 mg/dL and
B2000 mg/dL; ANCHOR: TG C200 mg/dL and \500
mg/dL and LDL-C C40 mg/dL and\115 mg/dL) entered a
12-week double-blind treatment period and were randomized
to receive either IPE 4 g/day, IPE 2 g/day, or matched
placebo.
2.2 Statistical Analysis
The primary efficacy endpoint for MARINE and ANCHOR
was the median placebo-adjusted percentage change in TG
levels from baseline to study end (week 12) in the two
active treatment groups. All efficacy analyses were per-
formed on the intent-to-treat (ITT) population, defined as
all randomized patients who had a baseline efficacy mea-
surement, received C1 dose of study drug, and had C1
post-randomization efficacy measurement. The efficacy
endpoints reported here include median placebo-adjusted
percentage changes from baseline to week 12 in ICAM-1,
Ox-LDL, Lp-PLA2, IL-6, and hsCRP levels for IPE (both
doses) compared to placebo. All were exploratory variables
except for Lp-PLA2, which was a secondary variable. In
MARINE, inflammation-related endpoints were evaluated
in nearly all patients; in ANCHOR, ICAM-1, Ox-LDL, and
IL-6 were measured in approximately the first 240 patients
of the ITT population.
The median difference of each variable in this analysis
(percentage change from baseline) between each IPE
treatment group and the placebo group was evaluated with
a non-parametric test using the Hodges-Lehmann medians
of the differences between treatment groups and the
Wilcoxon rank-sum test (data were non-parametric in
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distribution). For the exploratory endpoints assessed in this
analysis, a p value alpha of B0.05 was prespecified and no
adjustments were made for multiple comparisons; adjust-
ments were made for multiple comparisons for Lp-PLA2 as
this was a prespecified secondary endpoint (the p-values
were adjusted by applying Hommel’s multiple comparison
procedure to control the Type I error as pre-specified in the
study protocol). All statistical analyses were carried out
using SAS software version 8.2 or higher (SAS Institute,
Cary, NC, USA). Note that the two-sample Hodges-
Lehmann median does not estimate the difference of the
means or the difference of the medians; it estimates the
median of the differences, which, if the underlying distri-
butions are asymmetric, is a different quantity (i.e., the
Hodges-Lehmann median of the differences between treat-
ment groups does not exactly match the numerical differ-
ence between the two medians of the treatment groups).
2.3 Laboratory Measurements
Serum concentrations of ICAM-1 were measured using a
Quantikine Human sICAM-1 enzyme-linked immuno-
sorbent assay (R&D Systems, Minneapolis, MN, USA).
Plasma Ox-LDL concentrations were measured with a
solid-phase two-site enzyme immunoassay (Mercodia,
Winston Salem, NC, USA). Serum IL-6 concentrations
were measured using the Luminex fluorescent microsphere
technology. Serum Lp-PLA2 and hsCRP were measured as
previously described [16]. All assays were performed by
Medpace Reference Laboratories (Cincinnati, OH, USA;
Navi, Mumbai, India; and Leuven, Belgium) except for the
Lp-PLA2 assay, which was performed by Berkeley Heart-
Lab (Burlingame, CA, USA).
3 Results
3.1 Patient Characteristics
Table 1 includes the baseline demographics of patients in
the randomized populations of MARINE and ANCHOR,
and Table 2 lists the baseline lipid parameters in the ITT
populations. Baseline demographics and lipid parameters
were comparable among treatment groups within each
study. A higher percentage of patients in ANCHOR
(73 %) had diabetes mellitus than in MARINE (28 %),
reflecting that ANCHOR was a high CHD risk population.
Differences in baseline lipid parameters between the
studies were reflective of the different lipid entry criteria.
In MARINE, 55 % of the randomized patients were at
high risk for CHD; in ANCHOR, all patients were
required to have clinical CHD or CHD risk equivalents
(10-year risk C20 %).
3.2 Circulating Markers of Inflammation
Compared to placebo, IPE 4 g/day significantly decreased
several circulating markers of inflammation (Fig. 1 and
Table 3). In ANCHOR, IPE significantly decreased
Ox-LDL (13 %; p \ 0.0001) and Lp-PLA2 levels (19 %;
p \ 0.0001 [17]), and in MARINE, IPE significantly
decreased Lp-PLA2 levels (14 %; p \ 0.001 [16]). IPE
2 g/day did not significantly decrease levels of these
markers of inflammation, except for Lp-PLA2, for which
IPE 2 g/day produced a significant reduction in ANCHOR
(8.0 %; p \ 0.0001 [17]). Baseline hsCRP levels were
elevated in all groups (ranging from 1.8 to 2.2 mg/L;
Table 3). IPE 4 g/day significantly decreased hsCRP levels
by 36 % (p \ 0.01) in MARINE and by 22 % (p \ 0.001)
[17] in ANCHOR. IPE did not cause significant changes in
ICAM-1 or IL-6 levels.
3.3 hsCRP Statin Use Subgroup Analyses
Table 4 and Fig. 2 show that the changes from baseline for
IPE 4 g/day and placebo in hsCRP in patients not treated
with statins in the MARINE trial were 0.0 % and 31 %,
respectively, resulting in a statistically significant placebo-
adjusted reduction of 27 % (p = 0.0311). The changes
from baseline in hsCRP in patients treated with statins for
IPE 4 g/day and placebo were -31 and 43 %, respectively,
resulting in a statistically significant placebo-adjusted
reduction of 68 % (p = 0.0098). In ANCHOR, the changes
from baseline in hsCRP for IPE 4 g/day and placebo in
patients treated with atorvastatin were -12 and 31 %,
respectively, resulting in a statistically significant placebo-
adjusted reduction of 37 % (p = 0.0475). The changes
from baseline in hsCRP for IPE 4 g/day and placebo in
patients treated with rosuvastatin were -1.2 % and 15.2 %,
respectively, resulting in a statistically significant placebo-
adjusted reduction of 31 % (p = 0.0217). The changes
from baseline in hsCRP for IPE 4 g/day and placebo in
patients treated with simvastatin were 0.0 and 13.2 %,
respectively, resulting in a statistically non-significant
placebo-adjusted reduction of 13.6 % (p = 0.0755).
Compared to placebo in ANCHOR, IPE 4 g/day signifi-
cantly decreased hsCRP levels in patients receiving higher-
(29 %, p \ 0.05) and medium- (23 %, p \ 0.01) but not
lower-efficacy statin regimens (?4 %). However, the
number of patients receiving IPE 4 g/day in the lower-
efficacy statin treatment group was smaller (n = 16) than
those in the medium- (n = 132) and higher- (n = 69)
efficacy statin treatment groups. IPE 2 g/day did not sig-
nificantly decrease hsCRP in the subgroups analyzed.
Excluding the small numbers of subjects per group with
hsCRP levels [10 mg/L did not alter the conclusions on
hsCRP lowering.
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4 Discussion
IPE (formerly AMR101) is a high-purity prescription form
of EPA ethyl ester approved by the FDA as an adjunct to
diet to reduce TG levels in adult patients with severe
(C500 mg/dL) hypertriglyceridemia. MARINE evaluated
IPE in patients with very high TG levels (C500 mg/dL and
B2000 mg/dL) with and without statin therapy [16] and
ANCHOR evaluated IPE in statin-treated patients with
residually high TG (C200 mg/dL and \500 mg/dL) [17].














Age, years [mean (SD)] 51.9 (10.27) 53.4 (9.34) 53.4 (8.34) 61.1 (10.03) 61.8 (9.42) 61.2 (10.05)
Male [n (%)] 59 (76.6) 58 (76.3) 58 (76.3) 142 (60.9) 144 (61.0) 145 (62.2)
White [n (%)] 67 (87.0) 67 (88.2) 68 (89.5) 226 (97.0) 226 (95.8) 224 (96.1)
Weight, kg [mean (SD)] 93.2 (18.27) 92.1 (15.57) 93.0 (16.92) 94.5 (18.30) 95.5 (18.29) 97.0 (19.14)
BMI, kg/m2 [mean (SD)] 30.4 (4.29) 30.8 (4.24) 31.0 (4.25) 32.7 (4.99) 32.9 (4.98) 33.0 (5.04)
Diabetes [n (%)] 22 (28.6) 20 (26.3) 21 (27.6) 171 (73.4) 172 (72.9) 171 (73.4)
Baseline TG [750 mg/dL [n (%)] 29 (37.7) 29 (38.2) 32 (42.1) NA NA NA
Statin use [n (%)]a
Any 20 (26.0) 19 (25.0) 18 (23.7) 233 (100) 236 (100) 233 (100)
Atorvastatin NA NA NA 44 (18.9) 43 (18.2) 45 (19.3)
Simvastatin NA NA NA 134 (57.5) 136 (57.6) 133 (57.1)
Rosuvastatin NA NA NA 55 (23.6) 57 (24.2) 55 (23.6)
Statin efficacy regimens [n (%)]b
Lower NA NA NA 16 (6.9) 17 (7.2) 15 (6.4)
Medium NA NA NA 148 (63.5) 148 (62.7) 144 (61.8)
Higher NA NA NA 69 (29.6) 71 (30.1) 74 (31.8)
a 24.9 % (57/229) of patients in the MARINE study were on statin therapy
b Lower-efficacy statin regimens = simvastatin 5–10 mg; medium-efficacy statin regimens = rosuvastatin 5–10 mg, atorvastatin 10–20 mg,
simvastatin 20–40 mg, simvastatin 10–20 mg ? ezetimibe 5–10 mg; higher-efficacy statin regimens = rosuvastatin 20–40 mg, atorvastatin
40–80 mg, simvastatin 80 mg, simvastatin 40–80 mg ? ezetimibe 5–10 mg
BMI body mass index, NA data not applicable to study design, SD standard deviation, TG triglyceride
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Data are presented as median (interquartile range [IQR])
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglyceride
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Both these studies demonstrated that, compared to placebo,
IPE lowered TG, non-HDL-C, apo B, VLDL-C, and TC
levels without significantly raising LDL-C levels [16, 17].
Compared to placebo in MARINE, IPE 4 g/day sub-
stantially decreased hsCRP levels more in the statin-treated
patients (68 %) than in patients not receiving statin therapy
(27 %) (Table 4). Compared to placebo in ANCHOR, IPE
4 g/day decreased hsCRP levels by 37, 31, and 14 % in
patients taking atorvastatin, rosuvastatin, and simvastatin,
respectively. In ANCHOR, IPE 4 g/day significantly
decreased median placebo-adjusted Ox-LDL levels by 13
% (p \ 0.0001). In MARINE and ANCHOR, respectively,
IPE 4 g/day significantly decreased median placebo-
adjusted Lp-PLA2 by 14 % (p \ 0.001) [16] and 19 %
(p \ 0.0001) [17] and hsCRP levels by 36 % (p \ 0.01)
and 22 % (p \ 0.001) [17]. IPE did not significantly
change ICAM-1 or IL-6. Statins are known to decrease
hsCRP levels [18, 19], and subjects in both MARINE and
ANCHOR who received statin therapy were on stable
therapy prior to administration of IPE. Thus, the effects of
IPE on inflammatory markers in this study were in addition
to effects already achieved with statins. It is of interest
that in ANCHOR, IPE decreased hsCRP more in higher-
efficacy statin regimens.
Prior reports of EPA and/or DHA effects on LDL
oxidation [20, 21] or CRP [22–30] are inconsistent. As is
standard for reporting efficacy in placebo-controlled clini-
cal trials, and as per the statistical analyses defined for this
study, all measured efficacy parameters including hsCRP
and Ox-LDL were in comparison to placebo. Placebo-
adjusted comparisons between groups were based upon
median values, because TG and the other measured
parameters are commonly non-parametric, especially when
evaluated in patients with high or very high TG levels.
Despite variability inherent in these non-parametric
parameters, the data shown in Tables 3 and 4 support that
IPE 4 g/day (the dose approved for clinical use) consis-
tently decreased or resulted in no change from baseline
in hsCRP or Ox-LDL, and significantly decreased hsCRP
relative to the placebo groups. Compared to placebo, IPE 4
g/day consistently decreased hsCRP in patients treated with
or without statins, and among different statins and different
statin doses. The only exception was seen in patients
receiving lower-efficacy statin regimens, for whom IPE
4 g/day resulted in a mild increase in hsCRP, which was
not statistically significant and was numerically lower than
the increase seen with placebo. Some reports suggest
consumption of omega-3 fatty acids has little effect on
Lp-PLA2 levels in healthy patients [31, 32]. However, the
data in this analysis are consistent with the prior finding
that when 4 g per day of a prescription omega-3 fatty acid
(containing both EPA and DHA) were added to stable
statin therapy in hypertriglyceridemic patients, Lp-PLA2
levels were decreased [33].
Clinically, the degree by which LDL particles bind to
and are internalized by LDL receptors may be somewhat
dependent upon the LDL particle oxidation. Circulating
LDL particles with minimal oxidative modification may
continue to be recognized and internalized by body tissue
(such as liver) LDL receptors, while extensively oxidized
LDL particles may be less able to bind to LDL receptors
[34]. Conversely, oxidized LDL particles may undergo
Fig. 1 Median placebo-adjusted percentage change from baseline to
week 12 in levels of inflammatory markers (intent-to-treat population).
Lp-PLA2 data for MARINE from Bays et al. [16], Lp-PLA2 and hsCRP
data for ANCHOR from Ballantyne et al [17]. P values for Lp-PLA2
were adjusted for multiple comparisons. hsCRP high-sensitivity
C-reactive protein, ICAM-1 intercellular adhesion molecule-1, IL-6
interleukin-6, IPE icosapent ethyl, Lp-PLA2 lipoprotein-associated
phospholipase A2, NS not significant, Ox-LDL oxidized low-density
lipoprotein. *p \ 0.01; p \ 0.001; p \ 0.0001 vs. placebo
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preferential uptake by macrophage scavenger receptors,
which are not regulated by cellular cholesterol content
[34]. In the subendothelial space, the cholesterol-laden
macrophages may be transformed into foam cells, which
are commonly found within atherosclerotic lesions [34].
The net result is that the decreased recognition of circu-
latory Ox-LDL by LDL receptors may contribute to
increased circulating LDL-C levels, while the increased
uptake of Ox-LDL by subendothelial macrophages may
promote accumulation and death of foam cells, endothelial
toxicity, and promotion of atherogenesis.
Given that other omega-3 fatty acid therapies of EPA
and DHA in hypertriglyceridemic patients may (substan-
tially) increase LDL-C levels [35, 36], the lack of LDL-C
increases in MARINE and ANCHOR may be explained by
the lack of DHA in IPE. It is possible that the decrease in
LDL oxidation with IPE (albeit a non-significant reduction
in MARINE) observed in this analysis may increase LDL
receptor recognition and may play a role in the lack of rise
in LDL-C levels in MARINE and perhaps contribute to the
decrease in LDL-C levels found in ANCHOR.
The potential clinical significance of the anti-inflam-
matory effects of IPE may be supported by JELIS (Japan
EPA Lipid Intervention Study), wherein administration of
1.8 g/day of [98 % EPA ethyl ester (Mochida Pharma-
ceuticals, Tokyo, Japan) reduced major coronary events in
Japanese hypercholesterolemic patients receiving statin
therapy [37] despite only marginal differences in LDL-C,
HDL-C, and TG levels between the EPA ? statin and
statin-alone groups [37, 38]. Possible mechanisms wherein
omega-3 fatty acids may reduce CHD include anti-
inflammatory effects [15].
Limitations of this analysis include that: (i) all endpoints
were exploratory, with the exception of Lp-PLA2, which
was a secondary endpoint in both studies; (ii) patients were
not selected based upon elevated baseline inflammatory
marker levels, which may have limited the ability to detect
significant changes in some inflammatory markers (e.g.,
IL-6 and ICAM-1); and (iii) ICAM-1, Ox-LDL, and IL-6
were measured in a subset of the ANCHOR ITT population
and thus may lack statistical power to detect significant
changes. Additionally, neither MARINE nor ANCHOR
were of a design, or of sufficient size, to assess cardio-
vascular disease outcomes. To this end, the ongoing
REDUCE-IT (Reduction of Cardiovascular Events with
EPA – Intervention Trial; NCT01492361) will evaluate
whether IPE in combination with statin therapy is superior
to statin therapy alone in the reduction of long-term car-
diovascular events in approximately 8,000 high-risk
patients with mixed dyslipidemia.
5 Conclusion
This follow-up analysis of MARINE and ANCHOR
examined the placebo-adjusted effects of IPE (a high-pur-
ity prescription form of EPA ethyl ester approved by the
FDA as an adjunct to diet to reduce TG levels in adult
patients with severe [C500 mg/dL] hypertriglyceridemia)
on inflammatory markers associated with cardiovas-
cular disease and atherosclerosis in hypertriglyceridemic
Fig. 2 Median placebo-adjusted percentage change from baseline to
week 12 in hsCRP levels for statin use subgroups (intent-to-treat
population). a MARINE; b and c ANCHOR. IPE icosapent ethyl,
Lower-efficacy statin regimens simvastatin 5–10 mg, medium-efficacy
statin regimens rosuvastatin 5–10 mg, atorvastatin 10–20 mg, sim-
vastatin 20–40 mg, simvastatin 10–20 mg ? ezetimibe 5–10 mg,
higher-efficacy statin regimens rosuvastatin 20–40 mg, atorvastatin
40–80 mg, simvastatin 80 mg, simvastatin 40–80 mg ? ezetimibe
5–10 mg, NS not significant. *p \ 0.05; p \ 0.01 vs. placebo
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patients. In addition to the previously reported favorable
lipid effects of IPE [16, 17], this analysis showed that IPE
4 g/day significantly decreased Ox-LDL, Lp-PLA2, and
hsCRP levels and thus may offer a combination of bene-
ficial lipid and anti-inflammatory effects.
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